Bevezetés: Az FDG-PET-CT kiválóan alkalmas az életképes tumorszövetek kimutatására, jelentősége kiemelkedő az onkológiai diagnosztikában. Célkitűzés: A szerzők retrospektív vizsgálatukban a PET-CT-n mért metabolikus tumorválasz és a proliferációt jellemző Ki-67 marker összefüggéseit keresték. Módszerek: Harminc beteg esetében rögzítették a staging FDG-PET-CT felvételeken (kezelés előtt és után) a SUV (Standardized Uptake Value) és a méret változásait a primer tumor és az axillaris nyirokcsomó régió területén. A SUV-változást összevetették a core-biopsziás, valamint műtéti szövettan KI-67 értékével. Eredmények: A primer tumorok, valamint az axilla esetében is a metabolikus aktivitás, valamint – szerényebben ugyan – a méret is szignifikáns csökkenést mutatott a kezelés hatására. A Ki-67 szintén szignifikánsan csökkent. Szignifikáns korrelációt találtak a terápiát megelőző Ki-67 és SUV, a kezdeti Ki-67 és a SUV-változás, illetve a Ki-67-változás és a SUV-változás között is. Következtetések: A metabolikus változások érzékenyebb markernek bizonyultak a válaszkövetésben a morfometrián alapuló mérésnél a patológiai remisszió tükrében, még nem standardizált, klinikai körülmények között is. Orv. Hetil., 2012, 153, 1958–1964.
Anderson, E. D., Forrest, A. P., Hawkins, R. A., et al.: Primary systemic therapy for operable breast cancer. Br. J. Cancer, 1991, 63, 561–566.
Hawkins R. A. , 'Primary systemic therapy for operable breast cancer ' (1991 ) 63 Br. J. Cancer : 561 -566 .
Jacquillat, C., Weil, M., Baillet, F., et al.: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer, 1990, 66, 119–129.
Baillet F. , 'Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer ' (1990 ) 66 Cancer : 119 -129 .
Kaufmann, M., von Minckwitz, G., Smith, R., et al.: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J. Clin. Oncol., 2003, 21, 2600–2608.
Smith R. , 'International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations ' (2003 ) 21 J. Clin. Oncol. : 2600 -2608 .
Kaufmann, M., Hortobagyi, G. N., Goldhirsch, A., et al.: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol., 2006, 24, 1940–1949.
Goldhirsch A. , 'Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update ' (2006 ) 24 J. Clin. Oncol. : 1940 -1949 .
Bonadonna, G., Veronesi, U., Brambilla, C., et al.: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J. Natl. Cancer Inst., 1990, 82, 1539–1545.
Brambilla C. , 'Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more ' (1990 ) 82 J. Natl. Cancer Inst. : 1539 -1545 .
Sachelarie, I., Grossbard, M. L., Chadha, M., et al.: Primary systemic therapy of breast cancer. Oncologist, 2006, 11, 574–589.
Chadha M. , 'Primary systemic therapy of breast cancer ' (2006 ) 11 Oncologist : 574 -589 .
Kulka, J., Tokes, A. M., Toth, A. I., et al.: Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy. [Az emlőcarcinomák immunhisztokémiai fenotípusa előre jelzi a primer szisztémás kezelés hatékonyságát.] Magy. Onkol., 2009, 53, 335–343. [Hungarian]
Toth A. I. , 'Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy. [Az emlőcarcinomák immunhisztokémiai fenotípusa előre jelzi a primer szisztémás kezelés hatékonyságát.] ' (2009 ) 53 Magy. Onkol. : 335 -343 .
Kaufmann, M., Kubli, F.: Current state of chemosensitivity testing of tumors. Dtsch. Med. Wochenschr., 1983, 108, 150–154.
Kubli F. , 'Current state of chemosensitivity testing of tumors ' (1983 ) 108 Dtsch. Med. Wochenschr. : 150 -154 .
Fisher, B., Gunduz, N., Coyle, J., et al.: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res., 1989, 49, 1996–2001.
Coyle J. , 'Presence of a growth-stimulating factor in serum following primary tumor removal in mice ' (1989 ) 49 Cancer Res. : 1996 -2001 .
Fisher, B., Saffer, E., Rudock, C., et al.: Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res., 1989, 49, 2002–2004.
Rudock C. , 'Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice ' (1989 ) 49 Cancer Res. : 2002 -2004 .
Tardivon, A. A., Ollivier, L., El Khoury, C., et al.: Monitoring therapeutic efficacy in breast carcinomas. Eur. Radiol., 2006, 16, 2549–2558.
Khoury C. , 'Monitoring therapeutic efficacy in breast carcinomas ' (2006 ) 16 Eur. Radiol. : 2549 -2558 .
Wahl, R. L., Zasadny, K., Helvie, M., et al.: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J. Clin. Oncol., 1993, 11, 2101–2111.
Helvie M. , 'Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation ' (1993 ) 11 J. Clin. Oncol. : 2101 -2111 .
Schelling, M., Avril, N., Nahrig, J., et al.: Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol., 2000, 18, 1689–1695.
Nahrig J. , 'Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer ' (2000 ) 18 J. Clin. Oncol. : 1689 -1695 .
Smith, I. C., Welch, A. E., Hutcheon, A. W., et al.: Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J. Clin. Oncol., 2000, 18, 1676–1688.
Hutcheon A. W. , 'Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy ' (2000 ) 18 J. Clin. Oncol. : 1676 -1688 .
Bassa, P., Kim, E. E., Inoue, T., et al.: Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J. Nucl. Med., 1996, 37, 931–938.
Inoue T. , 'Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer ' (1996 ) 37 J. Nucl. Med. : 931 -938 .
Schwarz, J. D., Bader, M., Jenicke, L., et al.: Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J. Nucl. Med., 2005, 46, 1144–1150.
Jenicke L. , 'Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET ' (2005 ) 46 J. Nucl. Med. : 1144 -1150 .
Schwarz-Dose, J., Untch, M., Tiling, R., et al.: Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J. Clin. Oncol., 2009, 27, 535–541.
Tiling R. , 'Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose ' (2009 ) 27 J. Clin. Oncol. : 535 -541 .
Duch, J., Fuster, D., Muñoz, M., et al.: 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 1551–1557.
Muñoz M. , '18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer ' (2009 ) 36 Eur. J. Nucl. Med. Mol. Imaging : 1551 -1557 .
Kumar, A., Kumar, R., Seenu, V., et al.: The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur. Radiol., 2009, 19, 1347–1357.
Seenu V. , 'The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer ' (2009 ) 19 Eur. Radiol. : 1347 -1357 .
Wahl, R. L.: Current status of PET in breast cancer imaging, staging, and therapy. Semin. Roentgenol., 2001, 36, 250–260.
Wahl R. L. , 'Current status of PET in breast cancer imaging, staging, and therapy ' (2001 ) 36 Semin. Roentgenol. : 250 -260 .
Shankar, L. K., Hoffman, J. M., Bacharach, S., et al.: Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J. Nucl. Med., 2006, 47, 1059–1066.
Bacharach S. , 'Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials ' (2006 ) 47 J. Nucl. Med. : 1059 -1066 .
Wahl, R. L., Jacene, H., Kasamon, Y., et al.: From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med., 2009, 50 (Suppl. 1), 122S–150S.
Kasamon Y. , 'From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors ' (2009 ) 50 J. Nucl. Med. : 122S -150S .
Eisenhauer, E. A., Therasse, P., Bogaerts, J., et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45, 228–247.
Bogaerts J. , 'New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) ' (2009 ) 45 Eur. J. Cancer : 228 -247 .
Buck, A., Schirrmeister, H., Kühn, T., et al.: FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 1317–1323.
Kühn T. , 'FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters ' (2002 ) 29 Eur. J. Nucl. Med. Mol. Imaging : 1317 -1323 .
Buck, A. K., Schirrmeister, H., Mattfeldt, T., et al.: Biological characterisation of breast cancer by means of PET. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31 (Suppl. 1), S80–S87.
Mattfeldt T. , 'Biological characterisation of breast cancer by means of PET ' (2004 ) 31 Eur. J. Nucl. Med. Mol. Imaging : S80 -S87 .
Buban, T., Toth, L., Tanyi, M., et al.: Ki-67 – new faces of an old player. [Ki-67 – egy régi játékos új arcai.] Orv. Hetil., 2009, 150, 1059–1070. [Hungarian]
Tanyi M. , 'Ki-67 – new faces of an old player. [Ki-67 – egy régi játékos új arcai.] ' (2009 ) 150 Orv. Hetil. : 1059 -1070 .
De Azambuja, E., Cardoso, F., de Castro, G. Jr., et al.: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br. J. Cancer, 2007, 96, 1504–1513.
Castro G. , 'Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients ' (2007 ) 96 Br. J. Cancer : 1504 -1513 .
Colozza, M., Azambuja, E., Cardoso, F., et al.: Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Oncol., 2005, 16, 1723–1739.
Cardoso F. , 'Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? ' (2005 ) 16 Ann. Oncol. : 1723 -1739 .
Avril, N., Menzel, M., Dose, J., et al.: Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J. Nucl. Med., 2001, 42, 9–16.
Dose J. , 'Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis ' (2001 ) 42 J. Nucl. Med. : 9 -16 .
Bos, R., van der Hoeven, J. J., van der Wall, E., et al.: Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol., 2002, 20, 379–387.
Wall E. , 'Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography ' (2002 ) 20 J. Clin. Oncol. : 379 -387 .
Shimoda, W., Hayashi, M., Murakami, K., et al.: The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer, 2007, 14, 260–268.
Murakami K. , 'The relationship between FDG uptake in PET scans and biological behavior in breast cancer ' (2007 ) 14 Breast Cancer : 260 -268 .
Tchou, J., Sonnad, S. S., Bergey, M. R., et al.: Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol. Imaging Biol., 2010, 12, 657–662.
Bergey M. R. , 'Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer ' (2010 ) 12 Mol. Imaging Biol. : 657 -662 .